fbpx Skip to main content

THURSDAY, Nov. 12, 2020 (HealthDay News) — It is unclear whether the addition of nicotine electronic cigarettes to counseling leads to higher rates of smoking cessation than counseling alone among adults motivated to quit, according to the results of a study published in the Nov. 10 issue of the Journal of the American Medical Association.

Mark J. Eisenberg, M.D., from McGill University in Montreal, and colleagues randomly assigned adults motivated to quit smoking from November 2016 to September 2019 at 17 Canadian sites to nicotine e-cigarettes (128 participants), non-nicotine e-cigarettes (127 participants), or no e-cigarettes (121 participants) for 12 weeks, with all receiving individual counseling. Self-reported smoking status was assessed at 12 and 24 weeks.

The researchers found that the point prevalence of abstinence was significantly greater for nicotine e-cigarettes plus counseling versus counseling alone at 12 weeks (21.9 versus 9.1 percent; risk difference [RD], 12.8; 95 percent confidence interval [CI], 4.0 to 21.6), but not 24 weeks (17.2 versus 9.9 percent; RD, 7.3; 95 percent CI, –1.2 to 15.7). For non-nicotine e-cigarettes plus counseling versus counseling alone, the point prevalence for abstinence was not significantly different at 12 weeks (17.3 versus 9.1 percent; RD, 8.2; 95 percent CI, –0.1 to 16.6) but was significantly greater at 24 weeks (20.5 versus 9.9 percent; RD, 10.6; 95 percent CI, 1.8 to 19.4). Adverse events were common for all groups (nicotine e-cigarette with counseling, 94 percent; non-nicotine e-cigarette with counseling, 93 percent; counseling only, 73 percent); cough (64 percent) and dry mouth (53 percent) were the most frequently reported.

You May Also Like::  Food Insecurity Screenings and Food Referrals for Type 2 Diabetes

“Trial interpretation is limited by early termination and inconsistent findings for nicotine and nonnicotine e-cigarettes, suggesting further research is needed,” the authors write.

Two authors disclosed financial ties to Pfizer.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More